Whole transcriptome analysis of erlotinib treatment in EGFR-mutant cells
收藏官方服务：
资源简介：
Whole transcriptome analysis of erlotinib treatment in EGFR-mutant cells
应用场景：
创建时间：
2015-02-25
相关数据集
MEK inhibition profoundly reprograms myogenic super enhancers in mutant-RAS driven Rhabdomyosarcoma
Trametinib-treated rhabdomyosarcoma cells undergo transcriptional reprogramming akin to myogenic differentiation. This reprogramming is induced by loss of ERK-mediated inhibition of MYOG expression.
NIAID Data Ecosystem90
Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis
Dupilumab is a monoclonal antibody approved for the treatment of atopic dermatitis (AD); however, its effects on molecular, cellular, and immunological levels remain to be elucidated. In this study, b
NIAID Data Ecosystem60
Impact of ALK inhibition or phospho-deficient mutation of CDK9 on gene expression in ovarian cancer cells
The goal of this study is to determine the impact of ALK inhibition or phospho-deficient mutation of CDK9 on gene expresion profiles in ovarian cancer cells We performed bulk RNA sequencing on three c
NIAID Data Ecosystem50
Cancer Type-Specific SPOP Mutants Alter BET Protein Levels and Inhibitor Responses
It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Recently, cancer genome studies have delineated recurrent but divergent missense mutat
NIAID Data Ecosystem80
Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
Genomic amplification of 19q12 occurs in several cancer types including ovarian cancer where it is associated with primary treatment failure. We systematically attenuated expression of genes within th
NIAID Data Ecosystem50
